A 40-year-old Japanese man who had a medical history of hypokalemic periodic paralysis 4 months prior was hospitalized to undergo a cholecystectomy. Hypokalemia, nephrocalcinosis and alkaluria suggesting distal renal tubular acidosis (dRTA) were detected, but metabolic acidosis was not evident. An ammonium chloride/furosemide-fludrocortisone/bicarbonate loading test demonstrated a remarkable disability in urinary H + excretion. A novel heterozygous mutation in the ATP6V0A4 gene encoding the vacuolar H + -ATPase (V-ATPase) a4 subunit p.S544L was detected. Among cases of V-ATPase a4 mutations, this is the first case in which a heterozygous mutation developed to an incomplete or latent form of dRTA.
Introduction
Distal renal tubular acidosis (dRTA) is characterized by an inability to secrete H + in α-intercalated cells. The clinical manifestations of the disease consist of hyperchloremic metabolic acidosis, hypokalemia, hypercalciuria, hypocitraturia, urinary concentrating ability defect, recurrent urinary stone formation, nephrocalcinosis and bone demineralization. With regard to the genetic cause of dRTA, several currently known mutations have been identified in α-intercalated cells, including anion exchanger 1 (AE1), the B1 or a4 subunits of vacuolar H + -ATPase (V-ATPase) and cytosolic carbonic anhydrase 2 (CA2) [1] [2] [3] .
In cases of dRTA caused by V-ATPase mutations, the autosomal recessive form that manifests the disease in infancy is common [1] .
We herein describe an adult patient with incomplete dRTA caused by a novel heterogeneous mutation of V-ATPase a4. Among cases of dRTA due to V-ATPase a4 mutations, this is the first case that developed to an incomplete or late-onset form of the disease.
Case report
A 40-year-old Japanese man was admitted to our hospital to undergo a laparoscopic cholecystectomy. An unknown hypokalemia [ potassium (K) 2.7 mmol/L] was found and he was referred to our department presurgery. He had been hospitalized in another hospital for periodic paralysis due to unknown severe hypokalemia (K 1.7 mmol/L) 4 months prior. He and his father, who had died of a stroke, had been diagnosed with nephrocalcinosis in their 20s. None of his three siblings had any medical history. His physical and laboratory findings were as follows: height, 182 cm; weight, 81.5 kg; blood pressure, 120/78 mmHg. No abnormalities were observed in a physical examination. His audibility test was normal. In a blood examination, his serum creatinine level was elevated at 1.44 mg/dL (127.3 μmol/L). His serum K level was low, at 2.7 mmol/L, while his sodium (Na), chlorine (Cl), calcium (Ca), phosphorus (P) and magnesium (Mg) levels were all normal, at 144 mmol/L, 108 mmol/L, 8.7 mg/dL, 2.7 mg/dL and 2.6 mg/dL, respectively. The venous bicarbonate (HCO 3 À ) level was at the lower limit of the normal range, at 22.8 mmol/L. His blood anion gap was normal at 13.2. His complete blood counts were all normal. The levels of immunoglobulins and complements were all within normal limits, and he tested negative for antinuclear, anti-SS-A and anti-SS-B antibodies. The plasma renin activity (normal: 0.1-2) and plasma aldosterone concentration (normal: 35.7-240) were 0.7 ng/mL/h and 141.1 pg/mL, respectively. The spot urinary pH was 7.5 and the fractional excretion of K was inappropriately normal, at 10.3%, even in a hypokalemic state. The urinary Ca/creatinine ratio (mol) was 0. (Figures 1-3 ). The NH 4 Cl loading test demonstrated that the patient had dysfunction in both urinary acidification and net acid excretion under the acid loading condition ( Figure 1A-C) . In the furosemide-fludrocortisone loading test, the potential to secrete H + into the lumina at distal nephrons with an enhanced negative charge was extremely weak (Figure 2A) . In this test, instead of H + , the patient's K secretion increased sharply compared with a healthy control ( Figure 2B ).
In the bicarbonate loading test, the patient's basal H + secretion dysfunction was also demonstrated ( Figure 3A) ; conversely, the tubular maximal reabsorption rate of HCO 3 À (TmHCO 3 À ) was elevated compared with the control ( Figure 3B ). We performed comprehensive genetic testing for known causal genes of RTA in the patient using next-generation sequencing (NGS) technology based on the capturing method (Agilent Technologies). The genes SLC4A1 (encoding AE1), ATP6V1B1, ATP6V0A1, ATP6V0A4 (encoding the B1, a1 and a4 subunits of V-ATPase, respectively), SLC4A4 (encoding NBCe1-A), SLC34A1 (encoding NaPi-2a) and CA2 were all examined simultaneously. The detected mutations were narrowed down to those that might be disease-causing mutations according to the following two filters: one for novel variants that have not been reported dRTA by a novel heterozygous V-ATPase a4 mutation | 425 were orally administered to the patient. UpH was immediately measured using a glass electrode pH meter and E-H + and E-K (defined as urinary K/g·Cr) were calculated.
(A) In both the patient and the control, the level of E-H + reached its peak at 3 h after loading and then decreased. The level of the patient's E-H + during the test was extremely low compared with that of the control. (B) The patient's E-K transiently decreased at 1 h after loading, but then increased sharply compared with that of the control. Both the maximum and final level of the patient's E-K during the test were higher than that of the control. CO 2 level, which indicates a basal state of H + secretion accompanied by a dose-dependent accumulation of HCO3 À filtrate overflowing into the lumens of distal nephrons, was observed in the first half period of the test, while the levels of (U-B) CO2 were kept down, which was assumed to be an 'adaptive change' (i.e. suppression of H + secretion) against advanced metabolic alkalosis in the second half period. In the patient, however, (U-B) CO 2 remained almost unchanged at extremely low levels during the test. 426 | E. Imai et al.
previously or for variants with minor allele frequencies (MAFs) of up to 1% in the four single nucleotide polymorphism (SNP) databases [Human Genetic Variation Database (Japanese) [4] , 1000 Genomes [5], ESP6500 [6] , Exome Aggregation Consortium [7] ] and a second one for variants except for synonymous mutations if the variants are in the coding region. Consequently, only one mutation, which is a novel heterozygous mutation in ATP6V0A4 (exon 15, c.C1631T, p.S544L) was detected. As shown in Figure 4 , the detected variants were validated with conventional Sanger sequencing and the result was consistent with that of the NGS diagnosis. Moreover, to confirm whether a large structural variant such as a large deletion or insertion exists as the second mutation, we performed the copy number variation (CNV) analysis for all the targeted genes by using CONTRA (Supplementary Ref  S1) . Briefly, this is CNV detection software using NGS data, and it calls copy number gains and losses for each target region by comparing the normalized sequencing depth from control samples. We used the sequence data from seven individuals as controls and did not find any large deletions or insertions in the patient. The results of CNV detection extracting the ATP6V0A4 region are shown in Supplementary Table S1 . There were no regions where relative sequencing depth was significantly changed compared with the controls, indicating that this patient did not have large deletions in ATP6V0A4, thus he was believed to be a heterozygous carrier of the ATP6V0A4 mutation. In addition, it was confirmed at the same time that other tested genes (SLC4A1, SLC4A4, ATPV1B1, ATPV0A1, etc.) did not have any CNVs.
Discussion
As for the genetic causes of dRTA, the culprit protein can be detected in AE1, V-ATPase or CA2, expressed in α-intercalated cells. The late-onset or incomplete/mild type of dRTA is common in autosomal dominant, heterozygous mutations of AE1 [1] [2] [3] .
The clinical manifestation in the present case resembled cases caused by heterozygous AE1 mutations responsible for the following attributes: late onset, subclinical metabolic acidosis and complicated gallbladder stones. In dRTA from mutant AE1, an aberrant AE1 expressed on the cell membranes of erythrocytes can be a cause of hemolysis and gallbladder stones [1] ; however, the relationship between dRTA and gallbladder stones in the present case remains unclear because neither hemolysis nor AE1 mutations were evident. In cases of dRTA caused by mutant V-ATPase in either the B1 or a4 subunit, >40 gene mutations encoding each of those subunits have been reported to date [8] [9] [10] [11] [12] . The B1 subunit consists of a cytoplasmic V1 domain that hydrolyzes ATP, while the a4 transmembrane V0 domain translocates H + [13] . Cases of dRTA caused by mutant B1 have been recognized to develop deafness early in the disease course, while those caused by mutant a4 do not develop deafness or exhibit deafness with a highly variable phenotype range [13] [14] [15] [16] . In relation to the critical form of dRTA, hardly any difference between B1 and a4 in clinical manifestation was observed. However, according to a report from Turkey, polyuria and nephrocalcinosis were more common in dRTA patients with deafness compared with patients without deafness. This may suggest the difference between B1 and a4 in dRTA [17] . The difference in both the distribution and roles played by these two subunits may influence the clinical manifestation; however, the information derived from long-term observation was inconclusive.
In the critical form of mutant V-ATPase, the autosomal recessive form, showing an early onset (developing in infancy) and severe metabolic acidosis, was common until quite recently. However, incomplete dRTA presenting as impaired urinary acidification and/or recurrent renal stones from a heterozygous mutation or polymorphism of the B1 subunit has been reported [18, 19] . Zhang et al. [18] investigated a family of dRTA patients with a B1 subunit gene mutation ( p.F468fsX487) and demonstrated impairment of urinary acid acidification and net acid excretion in heterozygotes with normal plasma HCO 3 − . They also showed an aberrant distribution and expression of mutant B1 in the renal papilla of a heterozygote with severe kidney stones, and demonstrated insufficient V-ATPase activity of the heterologous expression of wild and mutant B1 using transfected mammalian cells and yeast. Most recently, Dhayat et al. [19] investigated a total of 555 recurrent stone formers and showed that the impairment of urinary acidification in acute NH 4 Cl loading, suggesting incomplete dRTA, was significantly observed in a population that was a heterozygous for the p.E161K SNP in subunit B1. In the present case, there was no variant in ATP6V1B1 (c.481G, p.161E). In regard to the a4 subunit of V-ATPase, to the best of our knowledge, the clinical features of a heterozygous a4 mutant in humans have not been well described to date, but in wild/ATP6V0a4-deletion hybrid mice, hyperchloremic metabolic acidosis under the condition of chronic acid loading has been proven [20] . It is clinically important that the incomplete dRTA from a novel heterozygous V-ATPase a4 subunit mutation in the present case presents as severe hypokalemia and chronic renal insufficiency. None of the six heterozygotes in a mutant B1 subunit described in a recent report [18] had this clinical feature. The loading tests for the present case clearly explained the mechanism of the clinical features, namely a urinary H + excretion dysfunction with compensatory changes in the proximal tubules (i.e. enhanced NH 4 þ production, TmHCO 3 À elevation) and urinary K loss instead of H + . No examinations of the patient's siblings have been done, but these changes may not be specific to the mutation of the present case, as the common mechanisms may be at work in any type of incomplete dRTA caused by a heterozygous mutant V-ATPase. In terms of the NGS analysis, especially in CNV, it has been well known that detecting relatively large structural variants is still a developing issue in NGS analysis. Moreover, particularly in cases of targeted resequencing like this one, it becomes more difficult to detect CNVs since the sequenced regions are very limited compared with the whole genome (Supplementary Ref S2) and thus detection sensitivity may decrease. Therefore, even though the CNV detection approach was done for NGS data, there remains the possibility that we could not detect such variants perfectly. This could be one of the limitations of this genetic analysis. 
